We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+0.7%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
+$50.8M
Cap. Flow
+$91.6M
Cap. Flow %
8.41%
Top 10 Hldgs %
59.85%
Holding
90
New
23
Increased
22
Reduced
6
Closed
21

Top Buys

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$43.7M
2
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$34.6M
3
PTCT icon
PTC Therapeutics
PTCT
+$14.6M
4
ASND icon
Ascendis Pharma A/S
ASND
+$12.1M
5
XLRN
Acceleron Pharma
XLRN
+$9.98M

Top Sells

Rank Stock Value
1
CHRS icon
Coherus Oncology
CHRS
+$13.5M
2
AZN icon
AstraZeneca
AZN
+$10.6M
3
ANAB icon
AnaptysBio
ANAB
+$7.16M
4
XNCR icon
Xencor
XNCR
+$6.52M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.43M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$127M 11.64%
1,099,824
+101,286
+10% +$12.1M
AMRN
2
Amarin Corp
AMRN
$284M
$101M 9.28%
260,415
– –
NTRA icon
3
Natera
NTRA
$37.5B
$85.5M 7.86%
3,100,560
– –
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$67.6M 6.22%
2,038,208
– –
OBSV
5
DELISTED
ObsEva SA Ordinary Shares
OBSV
$53.7M 4.94%
4,749,623
– –
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$49.3M 4.53%
481,270
– –
YMAB
7
DELISTED
Y-mAbs Therapeutics
YMAB
$48.1M 4.42%
2,104,278
– –
CHRS icon
8
Coherus Oncology
CHRS
$217M
$46.3M 4.25%
2,093,221
-775,000
-27% -$13.5M
NXTC icon
9
NextCure
NXTC
$17.3M
$37.8M 3.47%
+210,155
New +$43.7M
BOLD
10
DELISTED
Audentes Therapeutics, Inc
BOLD
$35.3M 3.25%
933,640
– –
KRTX
11
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$34.6M 3.18%
+1,729,352
New +$34.6M
MRUS
12
DELISTED
Merus
MRUS
$28.7M 2.64%
1,961,039
– –
NCNA
13
NuCana
NCNA
$5.37M
$23.5M 2.16%
453
– –
PTCT icon
14
PTC Therapeutics
PTCT
$6.37B
$16.6M 1.53%
+368,903
New +$14.6M
NVO
15
Novo Nordisk
NVO
$216B
$16.5M 1.52%
647,394
+151,926
+31% +$3.75M
AGN
16
DELISTED
Allergan plc
AGN
$14.1M 1.3%
84,433
-4,232
-5% -$586K
NBIX icon
17
Neurocrine Biosciences
NBIX
$17.7B
$13.2M 1.21%
155,860
+43,454
+39% +$3.57M
KNSA icon
18
Kiniksa Pharmaceuticals
KNSA
$4.83B
$12.5M 1.15%
922,700
– –
CHMA
19
DELISTED
Chiasma, Inc. Common Stock
CHMA
$12.2M 1.12%
1,630,221
– –
ITRM
20
DELISTED
Iterum Therapeutics
ITRM
$11.9M 1.09%
115,101
– –
HALO icon
21
Halozyme
HALO
$9.72B
$11.9M 1.09%
690,199
+288,870
+72% +$4.66M
HRTX icon
22
Heron Therapeutics
HRTX
$86.3M
$11.5M 1.05%
617,185
+383,534
+164% +$7.66M
TGTX icon
23
TG Therapeutics
TGTX
$8.58B
$10.9M 1%
1,261,384
+909,573
+259% +$6.88M
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$10.9M 1%
115,536
+50,505
+78% +$4.36M
XLRN
25
DELISTED
Acceleron Pharma
XLRN
$9.9M 0.91%
+241,043
New +$9.98M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q2 2019 Portfolio in Review

As of Q2 2019, Sofinnova Investments held 90 positions worth $1.09B, up 4.9% from $1.04B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Sofinnova Investments deployed $91.6M of net new capital in Q2 2019, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was NextCure: 210,155 shares worth $37.8M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 84% a quarter earlier.

On the sell side, the largest reduction was Coherus Oncology, an estimated $13.5M trimmed.

  • Sofinnova Investments's largest Q2 2019 buy was NextCure: 210,155 shares worth $37.8M.
  • Sofinnova Investments added most to Ascendis Pharma A/S in Q2 2019, an estimated $12.1M increase.
  • Sofinnova Investments's biggest Q2 2019 reduction was Coherus Oncology, cutting an estimated $13.5M.
  • Sofinnova Investments fully exited AstraZeneca in Q2 2019, selling an estimated $10.6M.
  • Sofinnova Investments's ten largest holdings make up 60% of its $1.09B portfolio in Q2 2019.
  • Sofinnova Investments opened 23 new positions and closed 21 in Q2 2019.
  • Sofinnova Investments's portfolio value rose 4.9% quarter-over-quarter to $1.09B.

Based on Sofinnova Investments's 13F filing for Q2 2019, filed 13 Aug 2019.